CoChat

Retinitis Pigmentosa: Review of Current Treatment

Open access
Wang, Angeline L., Knight, Darren K., Vu, Thanh-thao T., Mehta, Mitul C. · 2019 · International Ophthalmology Clinics
Cited by 73

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Wang, Angeline L. MD; Knight, Darren K. MD; Vu, Thanh-thao T. BSc; Mehta, Mitul C. MD, MS Author Information

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/iio.0000000000000256

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 75

  1. Daiger, 2007, Perspective on genes and mutations causing retinitis pigmentosa, Arch Ophthalmol, 125, 151, 10.1001/archopht.125.2.151 · DOI · Paper page
  2. Berson, 1993, A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa, Arch Ophthalmol, 111, 761, 10.1001/archopht.1993.01090060049022 · DOI · Paper page
  3. Berson, 2004, Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment, Arch Ophthalmol, 122, 1297, 10.1001/archopht.122.9.1297 · DOI · Paper page
  4. Berson, 2004, Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses, Arch Ophthalmol, 122, 1306, 10.1001/archopht.122.9.1306 · DOI · Paper page
  5. Hoffman, 2004, A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa, Am J Ophthalmol, 137, 704
  6. Hoffman, 2015, Docosahexaenoic acid slows visual field progression in x-linked retinitis pigmentosa: ancillary outcomes of the DHAX trial, Invest Ophthalmol Vis Sci, 56, 6646, 10.1167/iovs.15-17786 · DOI · Paper page
  7. Berson, 2010, Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A, Arch Ophthalmol, 128, 403, 10.1001/archophthalmol.2010.32 · DOI · Paper page
  8. Massof, 2010, How strong is the evidence that nutritional supplements slow the progression of retinitis pigmentosa?, Arch Ophthalmol, 128, 493, 10.1001/archophthalmol.2010.46 · DOI
  9. Massof, 1993, Supplemental vitamin A retards loss of ERG amplitude in retinitis pigmentosa, Arch Ophthalmol, 111, 751, 10.1001/archopht.1993.01090060039019 · DOI · Paper page
  10. Norton, 1993, A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa, Arch Ophthalmol, 111, 1460, 10.1001/archopht.1993.01090110018003 · DOI
  11. Siegel, 2013, ω-3 intake in patients with retinitis pigmentosa receiving vitamin A, JAMA Ophthalmol, 131, 267, 10.1001/jamaophthalmol.2013.590 · DOI
  12. Rayapudi, 2013, Vitamin A and fish oils for retinitis pigmentosa, Cochrane Database Syst Rev, 12, CD008428
  13. Sibulesky, 1999, Safety of <7500 RE (<25000 IU) vitamin A daily in adults with retinitis pigmentosa, Am J Clin Nutr, 69, 656, 10.1093/ajcn/69.4.656 · DOI
  14. Wheaton, 2003, Biological safety assessment of docosahexaenoic acid supplementation in a randomized clinical trial for X-linked retinitis pigmentosa, Arch Ophthalmol, 121, 1269, 10.1001/archopht.121.9.1269 · DOI · Paper page
  15. Hajali, 2008, The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography, Br J Ophthalmol, 92, 1065, 10.1136/bjo.2008.138560 · DOI · Paper page
  16. Ozdemir, 2005, Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa, Acta Ophthalmol Scand, 83, 248, 10.1111/j.1600-0420.2005.00395.x · DOI
  17. Garcia-Arumi, 2003, Vitreoretinal surgery for cystoid macular edema associated with retinitis pigmentosa, Ophthalmology, 110, 1164, 10.1016/S0161-6420(03)00259-8 · doi:10.1016/s0161-6420(03)00259-8
  18. Vinores, 1995, Blood-retinal barrier breakdown in retinitis pigmentosa: light and electron microscopic immunolocalization, Histol Histopathol, 10, 913
  19. Cox, 1988, Treatment of chronic macular edema with acetazolamide, Arch Ophthalmol, 106, 1190, 10.1001/archopht.1988.01060140350030 · DOI · Paper page
  20. Fishman, 1989, Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa, Arch Ophthalmol, 107, 1445, 10.1001/archopht.1989.01070020519031 · DOI · Paper page
  21. Moldow, 1998, The effect of acetazolamide on passive and active transport of fluorescein across the blood-retina barrier in retinitis pigmentosa complicated by macular oedema, Graefes Arch Clin Exp Ophthalmol, 236, 881, 10.1007/s004170050175 · doi:10.1007/s004170050175
  22. Chung, 2006, Optical coherence tomography in the diagnosis and monitoring of cystoid macular edema in patients with retinitis pigmentosa, Retina, 26, 922, 10.1097/01.iae.0000250008.83779.23 · doi:10.1097/01.iae.0000250008.83779.23
  23. Genead, 2010, Efficacy for sustained use of topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and Usher syndrome, Arch Ophthalmol, 128, 1146, 10.1001/archophthalmol.2010.172 · DOI
  24. Ikeda, 2012, The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa, Graefes Arch Clin Exp Ophthalmol, 250, 809, 10.1007/s00417-011-1904-5 · doi:10.1007/s00417-011-1904-5
  25. Ikeda, 2013, Therapeutic effect of prolonged treatment with topical dorzolamide for cystoid macular oedema in patients with retinitis pigmentosa, Br J Ophthalmol, 97, 1187, 10.1136/bjophthalmol-2012-303005 · DOI
  26. Fishman, 2007, Continued use of dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa, Br J Ophthalmol, 91, 743, 10.1136/bjo.2006.107466 · DOI
  27. Grover, 2006, Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa, Am J Ophthalmol, 141, 850, 10.1016/j.ajo.2005.12.030 · DOI · Paper page
  28. Liew, 2015, Efficacy and prognostic factors of response to carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa, Invest Ophthalmol Vis Sci, 56, 1531, 10.1167/iovs.14-15995 · DOI
  29. Apushkin, 2007, Rebound of cystoid macular edema with continued use of acetazolamide in patients with retinitis pigmentosa, Retina, 27, 1112, 10.1097/IAE.0b013e31805f6b79 · doi:10.1097/iae.0b013e31805f6b79
  30. Wielders, 2015, Prevention of cystoid macular edema after cataract surgery in nondiabetic and diabetic patients: a systematic review and meta-analysis, Am J Ophthalmol, 160, 968, 10.1016/j.ajo.2015.07.032 · doi:10.1016/j.ajo.2015.07.032
  31. Elma, 2010, Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema, Ophthalmology, 117, 1064, 10.1016/j.ophtha.2010.02.031 · DOI · Paper page
  32. Scorolli, 2007, Treatment of cystoid macular edema in retinitis pigmentosa with intravitreal triamcinolone, Arch Ophthalmol, 125, 759, 10.1001/archopht.125.6.759 · doi:10.1001/archopht.125.6.759
  33. Saraiva, 2003, Treatment of cystoid macular edema related to retinitis pigmentosa with intravitreal triamcinolone acetonide, Ophthalmic Surg Lasers Imaging, 34, 398, 10.3928/1542-8877-20030901-11 · doi:10.3928/1542-8877-20030901-11
  34. Barge, 2013, Intravitreal and subtenon depot triamcinolone as treatment for retinitis pigmentosa associated cystoid macular edema, Case Rep Ophthalmol Med, 2013, 591681
  35. Schaal, 2016, Subtenon triamcinolone for cystoid macular edema due to retinitis pigmentosa unresponsive to oral acetazolamide, Can J Ophthalmol, 51, e113, 10.1016/j.jcjo.2015.12.021 · doi:10.1016/j.jcjo.2015.12.021
  36. Srour, 2013, Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa, Graefes Arch Clin Exp Ophthalmol, 251, 1501, 10.1007/s00417-012-2249-4 · doi:10.1007/s00417-012-2249-4
  37. Saatci, 2013, Bilateral intravitreal dexamethasone implant for retinitis pigmentosa-related macular edema, Case Rep Ophthalmol, 4, 53, 10.1159/000350544 · DOI
  38. Ahn, 2014, The effect of an intravitreal dexamethasone implant for cystoid macular edema in retinitis pigmentosa: a case report and literature review, Ophthalmic Surg Lasers Imaging Retina, 45, 160, 10.3928/23258160-20140131-03 · DOI
  39. Örnek, 2016, Intravitreal dexamethasone implant (Ozurdex) for refractory macular edema secondary to retinitis pigmentosa, Turkish J Ophthalmol, 46, 179, 10.4274/tjo.60437 · doi:10.4274/tjo.60437
  40. Sudhalkar, 2017, Intravitreal dexamethasone implant for recalcitrant cystoid macular edema secondary to retinitis pigmentosa: a pilot study, Graefes Arch Clin Exp Ophthalmol, 255, 1369, 10.1007/s00417-017-3660-7 · DOI
  41. Mansour, 2018, Intravitreal dexamethasone implant in retinitis pigmentosa-related cystoid macular edema, Retina, 38, 416, 10.1097/IAE.0000000000001542 · DOI
  42. Querques, 2009, Intravitreal pegaptanib sodium (Macugen) for refractory cystoid macular edema in pericentral retinitis pigmentosa, Int Ophthalmol, 29, 103, 10.1007/s10792-007-9175-1 · doi:10.1007/s10792-007-9175-1
  43. Melo, 2007, Intravitreal injection of bevacizumab for cystoid macular edema in retinitis pigmentosa, Acta Ophthalmol Scand, 85, 461, 10.1111/j.1600-0420.2006.00872.x · doi:10.1111/j.1600-0420.2006.00872.x
  44. Yuzbasioglu, 2009, Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa, Curr Eye Res, 34, 231, 10.1080/02713680802710692 · DOI
  45. Artunay, 2009, Intravitreal ranibizumab in the treatment of cystoid macular edema associated with retinitis pigmentosa, J Ocul Pharmacol Ther, 25, 545, 10.1089/jop.2009.0089 · DOI
  46. Moustafa, 2015, Intravitreal aflibercept (Eylea) injection for cystoid macular edema secondary to retinitis pigmentosa—a first case report and short review of the literature, BMC Ophthalmol, 15, 44, 10.1186/s12886-015-0033-z · DOI
  47. Strong, 2016, Treatment of retinitis pigmentosa-associated cystoid macular oedema using intravitreal aflibercept (Eylea) despite minimal response to ranibizumab (Lucentis): a case report, Case Rep Ophthalmol, 7, 389, 10.1159/000448427 · doi:10.1159/000448427
  48. Koitschev, 2015, Extraocular surgical approach for placement of subretinal implants in blind patients: lessons from cochlear-implants, J Ophthalmol, 2015, 842518, 10.1155/2015/842518 · DOI
  49. Noorwez, 2008, A high-throughput screening method for smallmolecule pharmacologic chaperones of misfolded rhodopsin, Invest Ophthalmol Vis Sci, 49, 3224, 10.1167/iovs.07-1539 · DOI
  50. Monti, 2009, Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection, Curr Mol Pharmacol, 2, 95, 10.2174/1874467210902010095 · doi:10.2174/1874467210902010095 · Paper page
  51. Clemson, 2011, Therapeutic potential of valproic acid for retinitis pigmentosa, Br J Ophthalmol, 95, 89, 10.1136/bjo.2009.175356 · DOI
  52. Sisk, 2012, Valproic acid treatment may be harmful in non-dominant forms of retinitis pigmentosa, Br J Ophthalmol, 96, 1154, 10.1136/bjophthalmol-2012-301950 · DOI
  53. Todd, 2017, Valproic acid for a treatment of retinitis pigmentosa: reasons for optimism and caution, J Neurosci, 37, 5215, 10.1523/JNEUROSCI.0774-17.2017 · DOI
  54. Shanmugam, 2012, Effect of short-term oral valproic acid on vision and visual field in retinitis pigmentosa, Ophthalmol Ther, 1, 6, 10.1007/s40123-012-0006-8 · doi:10.1007/s40123-012-0006-8
  55. Kumar, 2014, Efficacy of oral valproic acid in patients with retinitis pigmentosa, J Ocul Pharmacol Ther, 30, 580, 10.1089/jop.2013.0166 · DOI
  56. Iraha, 2016, Efficacy of valproic acid for retinitis pigmentosa patients: a pilot study, Clin Ophthalmol, 10, 1375, 10.2147/OPTH.S109995 · DOI
  57. Bhalla, 2013, Long-term follow-up for efficacy and safety of treatment of retinitis pigmentosa with valproic acid, Br J Ophthalmol, 97, 895, 10.1136/bjophthalmol-2013-303084 · DOI
  58. Totan, 2017, The adverse effects of valproic acid on visual functions in the treatment of retinitis pigmentosa, Indian J Ophthalmol, 65, 984, 10.4103/ijo.IJO_978_16 · DOI
  59. LaVail, 1998, Protection of mouse photoreceptors by survival factors in retinal degenerations, Invest Ophthalmol Vis Sci, 39, 592
  60. Cayouette, 1998, Intraocular gene transfer of ciliary neurotrophic factor prevents death and increases responsiveness of rod photoreceptors in the retinal degeneration slow mouse, J Neurosci, 18, 9282, 10.1523/JNEUROSCI.18-22-09282.1998 · DOI · Paper page
  61. Tao, 2002, Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa, Invest Ophthalmol Vis Sci, 43, 3292
  62. Liang, 2011, AAV-mediated delivery of ciliary neurotrophic factor prolongs photoreceptor survival in the rhodopsin knockout mouse, Mol Ther, 3, 241, 10.1006/mthe.2000.0252 · DOI · Paper page
  63. Sieving, 2006, Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants, Proc Natl Acad Sci USA, 103, 3896, 10.1073/pnas.0600236103 · DOI · Paper page
  64. Birch, 2013, Ciliary neurotrophic factor retinitis pigmentosa study G. Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa, Am J Ophthalmol, 156, 283, 10.1016/j.ajo.2013.03.021 · DOI · Paper page
  65. Tao, 2016, The transcoreal electrical stimulation as a novel therapeutic strategy against retinal and optic neuropathy: a review of experimental and clinical trials, Int J Ophthalmol, 9, 914
  66. Schatz, 2011, Transcorneal electrical stimulation for patients with retinitis pigmentosa: a prospective, randomized, sham-controlled exploratory study, Invest Ophthalmol Vis Sci, 52, 4485, 10.1167/iovs.10-6932 · DOI · Paper page
  67. Schatz, 2017, Transcorneal Electrical stimulation for patients with retinitis pigmentosa: a prospective, randomized, sham-controlled follow-up study over 1 year, Invest Ophthalmol Vis Sci, 58, 257, 10.1167/iovs.16-19906 · DOI · Paper page
  68. MacLaren, 2016, Gene therapy and stem cell transplantation in retinal disease: the new frontier, Ophthalmology, 123, 98, 10.1016/j.ophtha.2016.06.041 · DOI · Paper page
  69. Thompson, 2015, Advancing therapeutic strategies for inherited retinal degeneration: recommendations from the monaciano symposium, Invest Ophthalmol Vis Sci, 56, 918, 10.1167/iovs.14-16049 · DOI · Paper page
  70. Busskamp, 2012, Optogenetic therapy for retinitis pigmentosa, Gene Ther, 19, 169, 10.1038/gt.2011.155 · DOI · Paper page
  71. Mead, 2015, Stem cell treatment of degenerative eye disease, Stem Cell Res, 14, 243, 10.1016/j.scr.2015.02.003 · DOI · Paper page
  72. Kim, 2017, Epiretinal membrane formation after intravitreal autologous stem cell implantation in a retinitis pigmentosa patient, Retin Cases Brief Rep, 11, 227, 10.1097/ICB.0000000000000327 · DOI
  73. Satarian, 2017, Intravitreal injection of bone marrow mesenchymal stem cells in patients with advanced retinitis pigmentosa; a safety study, J Ophthalmic Vis Res, 12, 58, 10.4103/2008-322X.200164 · DOI
  74. Park, 2015, Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings, Invest Ophthalmol Vis Sci, 56, 81, 10.1167/iovs.14-15415 · DOI · Paper page
  75. Siqueria, 2011, Intravitreal injection of autologous bone marrow-derived mononuclear cells for hereditary retinal dystrophy: a phase I trial, Retina, 31, 1207, 10.1097/IAE.0b013e3181f9c242 · DOI

Cited by

See all 73

Metadata

Authors
Wang, A. L., Knight, D. K., Vu, T.-T. T., & Mehta, M. C.
Venue
International Ophthalmology Clinics
Published
2019
Volume
59
Issue
1
Pages
263-280
ISSN
0020-8167 (ISSN-L)
OpenAlex
W2905827260
Cited by
73
References
15
FWCI
1.80
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Retinitis Pigmentosa: Review of Current Treatment. https://app.cochat.ai/papers/10.1097/iio.0000000000000256
The paper
Wang, A. L., Knight, D. K., Vu, T.-T. T., & Mehta, M. C. (2019). Retinitis Pigmentosa: Review of Current Treatment. International Ophthalmology Clinics. https://doi.org/10.1097/iio.0000000000000256

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.